Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (221-230 of 275) with videos related to

Pageof 28
Sort By:
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
Journal for Immunotherapy of Cancer|May 27, 2025
Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus studyLajos Pusztai, Vernon K Sondak, Raquel Aguiar-Ibáñez, et al.
Scientific Reports|December 14, 2020
Blockage of interleukin-1β with canakinumab in patients with Covid-19Lorenza Landi, Claudia Ravaglia, Emanuele Russo, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapyMaurice Pérol, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyFiona Blackhall, Kevin Jao, Laurent Greillier, et al.
The Lancet. Oncology|September 9, 2021
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trialCarmine Pinto, Paolo Andrea Zucali, Maria Pagano, et al.
Cancers|August 27, 2021
Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?Marco Mazzotta, Laura Pizzuti, Eriseld Krasniqi, et al.
Journal for Immunotherapy of Cancer|August 23, 2023
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLCPaola Trono, Annalisa Tocci, Belinda Palermo, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancerLucio Crinò, Giuseppe Bronte, Paolo Bidoli, et al.
Pageof 28

Showing results (221-230 of 275) with videos related to

Sort By:
Pageof 28
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
Journal for Immunotherapy of Cancer|May 27, 2025
Clinical factors influencing retreatment with anti-PD-(L)1 therapies after treatment in early-stage cancers: a modified Delphi consensus studyLajos Pusztai, Vernon K Sondak, Raquel Aguiar-Ibáñez, et al.
Scientific Reports|December 14, 2020
Blockage of interleukin-1β with canakinumab in patients with Covid-19Lorenza Landi, Claudia Ravaglia, Emanuele Russo, et al.
Journal for Immunotherapy of Cancer|April 5, 2019
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access programElena Verzoni, Giacomo Cartenì, Enrico Cortesi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 23, 2016
Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapyMaurice Pérol, Tudor-Eliade Ciuleanu, Oscar Arrieta, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2021
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE StudyFiona Blackhall, Kevin Jao, Laurent Greillier, et al.
The Lancet. Oncology|September 9, 2021
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trialCarmine Pinto, Paolo Andrea Zucali, Maria Pagano, et al.
Cancers|August 27, 2021
Role of Chemotherapy in Vulvar Cancers: Time to Rethink Standard of Care?Marco Mazzotta, Laura Pizzuti, Eriseld Krasniqi, et al.
Journal for Immunotherapy of Cancer|August 23, 2023
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLCPaola Trono, Annalisa Tocci, Belinda Palermo, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2019
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancerLucio Crinò, Giuseppe Bronte, Paolo Bidoli, et al.
Pageof 28